Martin John Glennie

This inventor holds 13 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 9 EPO patents. Top assignees: University of Southampton, Cancer Research Technology Limited, Genmab A+s. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin John Glennie. Retrieved from https://idiyas.com/inventor/martin-john-glennie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 7)

% Patents Active = 76.9

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 84(Granted Patents)

Location History:

Swaithling, GB (2010)
Southampton, GB (2013 - 2023)

Company Filing History:

7 out of 252

University of Southampton

patents

4 out of 268

Cancer Research Technology Limited

Years Active: 2010-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12527866 - COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES (2026-01-20),

2. 12325754 - Cancer and B-cell related disease therapy (2025-06-10),

3. 11780929 - Immunomodulatory antibodies (2023-10-10),

4. 11623005 - Combined use of FcγRIIb (CD32B) and CD20 specific antibodies (2023-04-11),

5. 11447549 - Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody (2022-09-20),

6. 11059898 - Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof (2021-07-13),

7. 11001638 - Immunomodulatory antibodies (2021-05-11),

8. 10525129 - Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies (2020-01-07),

9. 9926374 - Human immune therapies using a CD27 agonist in combination with another immune agonist to treat cancer (2018-03-27),

10. 9248183 - Human immune therapies using a CD27 agonist alone or in combination with other immune modulators (2016-02-02),

11. 8529902 - Human monoclonal antibodies against CD20 (2013-09-10),

12. 8481029 - Human immune therapies using a CD27 agonist alone or in combination with other immune modulators (2013-07-09),

13. 7850962 - Human monoclonal antibodies against CD20 (2010-12-14),

Title: The Legacy of Martin John Glennie: Pioneering Inventor from Southampton

Introduction: Martin John Glennie, a distinguished inventor hailing from Southampton, GB, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Martin John Glennie holds several patents in various technological domains, including advancements in renewable energy systems, smart home devices, and medical equipment.

Career Highlights: With a career spanning over three decades, Martin John Glennie has been at the forefront of innovation, leading research and development teams in creating cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Martin John Glennie has collaborated with leading universities, research institutions, and multinational corporations to bring his visionary ideas to life. His collaborative efforts have resulted in the successful commercialization of numerous inventions.

Conclusion: Martin John Glennie's relentless pursuit of innovation and his passion for pushing the boundaries of technology have cemented his legacy as a pioneering inventor in Southampton and beyond.

Profile summary based on public USPTO records.